Literature DB >> 1718695

Silent ischaemia in the 1990s.

D Tzivoni1.   

Abstract

Silent myocardial ischaemia (significant ST depression without chest pain) is a common occurrence in most forms of coronary heart disease and can be associated with permanent changes in myocardial structure. The haemodynamic and ECG manifestations of silent episodes are similar to those observed in painful ischaemia. Exercise testing is the most appropriate method for assessing the severity of coronary artery disease; increased sensitivity can be obtained by combining it with radionuclide scintigraphy or ventriculography. Ambulatory ECG monitoring may fail to detect ischaemic changes revealed by exercise provocation. The treatment approach should depend on the degree of ischaemia. Numerous clinical investigations in stable and unstable angina and in patients with a previous myocardial infarction indicate that the prognosis of patients with myocardial ischaemia does not depend on whether the ischaemia is silent or symptomatic. Silent and symptomatic episodes alone represent the same degree of coronary disease. Moreover, it appears that ischaemic episodes are a more powerful adverse prognostic influence than left ventricular function or the extent of coronary artery disease. All anti-ischaemic agents, such as beta-blockers, calcium antagonists and nitrates, and interventions such as coronary balloon angioplasty or coronary bypass surgery, are very effective treatments for myocardial ischaemia. All efforts should be made to prevent ischaemic episodes, whether silent or symptomatic, since the severity of disease rather than the presence or absence of symptoms more accurately reflects the need for intervention.

Entities:  

Mesh:

Year:  1991        PMID: 1718695     DOI: 10.2165/00003495-199100421-00010

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  48 in total

1.  Coronary arterial reperfusion. III. Early and late effects on regional myocardial function and dimensions in conscious dogs.

Authors:  P Theroux; J Ross; D Franklin; W S Kemper; S Sasayama
Journal:  Am J Cardiol       Date:  1976-11-04       Impact factor: 2.778

2.  Comparison of mortality and myocardial infarction rates in stable angina pectoris with and without ischemic episodes during daily activities.

Authors:  D Tzivoni; G Weisz; A Gavish; D Zin; A Keren; S Stern
Journal:  Am J Cardiol       Date:  1989-02-01       Impact factor: 2.778

3.  Comparison of exercise tests and 24-hour ambulatory electrocardiographic monitoring in detection of ST-T changes.

Authors:  E Wolf; D Tzivoni; S Stern
Journal:  Br Heart J       Date:  1974-01

4.  Risk of developing an acute myocardial infarction or sudden coronary death in patients with exercise-induced silent myocardial ischemia. A report from the Coronary Artery Surgery Study (CASS) registry.

Authors:  D A Weiner; T J Ryan; C H McCabe; G Ng; B R Chaitman; L T Sheffield; F E Tristani; L D Fisher
Journal:  Am J Cardiol       Date:  1988-12-01       Impact factor: 2.778

Review 5.  Relation of silent myocardial ischemia to ventricular arrhythmias and sudden death.

Authors:  E A Amsterdam
Journal:  Am J Cardiol       Date:  1988-11-03       Impact factor: 2.778

6.  Incidence of ventricular arrhythmias during transient myocardial ischemia in patients with stable coronary artery disease.

Authors:  D Hausmann; P Nikutta; H J Trappe; W G Daniel; P Wenzlaff; P R Lichtlen
Journal:  J Am Coll Cardiol       Date:  1990-07       Impact factor: 24.094

7.  Effect of propranolol on indices of intermittent myocardial ischemia, assessed by exercise testing and ambulatory ST-segment monitoring.

Authors:  N S Khurmi; M J Bowles; M J O'Hara; E B Raftery
Journal:  Clin Cardiol       Date:  1986-08       Impact factor: 2.882

8.  Transient asymptomatic S-T segment depression during daily activity.

Authors:  S J Schang; C J Pepine
Journal:  Am J Cardiol       Date:  1977-03       Impact factor: 2.778

9.  Electrophysiologic studies before and after myocardial revascularization in patients with life-threatening ventricular arrhythmias.

Authors:  H Garan; J N Ruskin; J P DiMarco; W M Derkac; C W Akins; W M Daggett; W G Austen; M J Buckley
Journal:  Am J Cardiol       Date:  1983-02       Impact factor: 2.778

10.  Prolonged derangements of canine myocardial purine metabolism after a brief coronary artery occlusion not associated with anatomic evidence of necrosis.

Authors:  L W DeBoer; J S Ingwall; R A Kloner; E Braunwald
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

View more
  1 in total

Review 1.  Gallopamil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in ischaemic heart disease.

Authors:  R N Brogden; P Benfield
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.